Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity
of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or
metastatic breast cancer over-expressing Her-2, who have not received chemotherapy treatment
in the advanced disease setting.